Johnson & Johnson (JNJ) posts strong Q2 results, lifts 2021 outlook

July 21, 2021 06:40 AM PDT | By Kiran Murali

Google News:

Johnson & Johnson (JNJ) posts strong Q2 results, lifts 2021 outlook — Image source: rafapress, Shutterstock.com

Recent News

DoubleVerify Sees Update in Digital Ad Tech Sector Russell 1000

Pagaya Technologies PGY Gains Support Nasdaq Index Stocks Watch

Oceaneering International OII Sees Institutional Growth on NYSE Compos...

GAMMA Expands Stake in Valvoline Inc Amid Market Movements S&P 500

Summary

Johnson & Johnson’s net earnings jumped 73 percent in the second quarter.

The company now anticipates its full-year revenue to grow up to 14.5 percent.

The medical device unit sales climbed 62.7 percent to US$6.97 billion.

Johnson & Johnson (NYSE:JNJ) on July 21 reported strong second-quarter results and raised its revenue and profit guidance for full-year 2021.

The healthcare giant posted approximately 73 percent year-over-year growth in its second-quarter net earnings on a 27.1 percent increase in its sales. The sales were supported by robust topline growth across its medical device and pharmaceutical businesses.

Second-quarter update

Johnson & Johnson’s second-quarter net earnings totaled US$6.28 billion, or US$2.35 per share, compared with US$3.63 billion, or US$1.36 per share, in the year-ago period. Adjusted net earnings surged around 49 percent year over year to US$6.63 billion, or US$2.48 per share.

Reported sales during the three months came in at US$23.31 billion, up from US$18.34 billion in the second quarter previous year. The medical device unit sales climbed 62.7 percent to US$6.97 billion while the sales in the pharmaceutical unit grew 17.2 percent to US$12.60 billion. The consumer health unit recorded US$3.74 billion in sales, up 13.3 percent.

Johnson & Johnson said its single-dose COVID-19 vaccine generated US$164 million sales globally during the June quarter, compared to US$100 million in the January-March quarter.

Source: Pixabay

Full-year forecast

Annual revenue is now projected to come in between US$$93.8 billion and US$94.6 billion, which represents a year over year growth of up to 14.5 percent. Previously, the company was expecting revenue to be in the range of US$90.6 billion to US$91.6 billion.

Johnson & Johnson anticipates adjusted EPS to be in the range of US$9.60 to US$$9.70, compared with the earlier estimate range of US$9.42 to US$9.57.

Meanwhile, Johnson & Johnson’s board has declared a third-quarter dividend of US$1.06 per share.

Share performance

Johnson & Johnson currently has a market capitalization of approximately US$443.60 billion. The company has a P/E ratio of 29.75 while its stock returned 7 percent year to date.

The shares were trading in the range of US$133.65 to US$173.65 in the last 52-week period.

Johnson & Johnson’s stock, which closed at US$168.45 on Tuesday, rose 0.92 percent in the pre-market trading on Wednesday.

Please note: The above constitutes a preliminary view and any interest in stocks/cryptocurrencies should be evaluated further from an investment point of view.

The reference data in this article has been partly sourced from Refinitiv.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.